Related Experiment Videos
Antibiotic resistance problems with Helicobacter pylori.
T Alarcón1, D Domingo, M López-Brea
1Department of Clinical Microbiology, Hospital Universitario de la Princesa, Madrid, Spain. talarcon1@yahoo.com
International Journal of Antimicrobial Agents
|July 2, 1999
Summary
Antibiotic resistance in Helicobacter pylori, particularly metronidazole resistance, is a growing global concern. This resistance significantly impacts the effectiveness of standard eradication therapies, leading to treatment failures.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Helicobacter pylori is a common human pathogen associated with various gastric conditions.
- Standard dual or triple antibiotic therapies are frequently used for H. pylori eradication.
- In vitro susceptibility does not always translate to clinical eradication success.
Purpose of the Study:
- To investigate the prevalence of antibiotic resistance in Helicobacter pylori strains.
- To understand the correlation between antibiotic resistance and treatment outcomes.
Main Methods:
- Review of in vitro susceptibility testing methods including disk diffusion, agar dilution, and E-test.
- Analysis of global and regional resistance rates for key antibiotics like metronidazole and clarithromycin.
Main Results:
- Metronidazole resistance in H. pylori is widespread globally, with significantly higher rates in developing countries (up to 80-90% in Africa).
- Clarithromycin resistance is generally lower (below 10%), but exceptionally high rates are reported in specific regions like Peru.
- Resistance to metronidazole or clarithromycin is linked to treatment failure in H. pylori eradication regimens.
Conclusions:
- Antibiotic resistance, especially to metronidazole, poses a significant challenge for H. pylori eradication.
- Current therapeutic strategies may be compromised by the increasing prevalence of resistant H. pylori strains.
- Monitoring resistance patterns is crucial for optimizing H. pylori treatment protocols.